EUVIMEDEUVIMED entdecken
Open Access

Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders

Elahe Amini iD, Mohammad Rohani iD, Anthony E Lang iD, Zahra Azad iD, Seyed Amir Hassan Habibi iD, Afagh Alavi iD, Gholamali Shahidi iD, Maziar Emamikhah iD, Ahmad Chitsaz iD

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.13933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Elahe Amini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Skull Base Research Center, The Five Senses Health Institute, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Pantothenate Kinase-Associated Neurodegeneration, Iron Metabolism Disorders, Hemochromatosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute for Medical Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurodegeneration with Brain Iron Accumulation (NBIA) disorder is a group of ultra‐orphan hereditary diseases with very limited data on its course.

Objectives

To estimate the probability of preserving ambulatory ability and survival in NBIA.

Methods

In this study, the electronic records of the demographic data and clinical assessments of NBIA patients from 2012 to 2023 were reviewed. The objectives of the study and factors impacting them were investigated by Kaplan–Meier and Cox regression methods.

Results

One hundred and twenty‐two genetically‐confirmed NBIA patients consisting of nine subtypes were enrolled. Twenty‐four and twenty‐five cases were deceased and wheelchair‐bound, with a mean disease duration of 11 ± 6.65 and 9.32 ± 5 years. The probability of preserving ambulation and survival was 42.9% in 9 years and 28.2% in 15 years for classical Pantothenate Kinase‐Associated Neurodegeneration (PKAN, n = 18), 89.4% in 7 years and 84.7% in 9 years for atypical PKAN (n = 39), 23% in 18 years and 67.8% in 14 years for Mitochondrial Membrane Protein‐Associated Neurodegeneration (MPAN, n = 23), 75% in 20 years and 36.5% in 33 years for Kufor Rakeb Syndrome (KRS, n = 17), respectively. The frequencies of rigidity, spasticity, and female gender were significantly higher in deceased cases compared to surviving patients. Spasticity was the only factor associated with death ( P value = 0.03).

Conclusions

KRS had the best survival with the most extended ambulation period. The classical PKAN and MPAN cases had similar progression patterns to loss of ambulation ability, while MPAN patients had a slower progression to death. Spasticity was revealed to be the most determining factor for death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pantothenate Kinase-Associated NeurodegenerationIron Metabolism DisordersHemochromatosisNeurodegenerative DiseasesParkinsonian DisordersHumansFemaleBrainMuscle SpasticityWalkingIron

Stichwörter der Autor:innen

NBIAambulationironmuscle spasticitysurvival

Substanzen

Iron

Autor:innen und Institutionen

  • Skull Base Research Center, The Five Senses Health Institute, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Neurology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital and Edmond J. Safra Program in Parkinson Disease, University of Toronto, Toronto, Ontario, Canada.
  • Genetics Research Center, The University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.

ORCID-Profile: Elahe Amini, Mohammad Rohani, Anthony E Lang, Zahra Azad, Seyed Amir Hassan Habibi, Afagh Alavi, Gholamali Shahidi, Maziar Emamikhah, Ahmad Chitsaz

Förderung

  • National Institute for Medical Research Development

Zitieren

APA

Amini, E., Rohani, M., Lang, A. E., Azad, Z., Habibi, S. A. H., Alavi, A., Shahidi, G., Emamikhah, M., & Chitsaz, A. (2024). Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13933

Vancouver

Amini E, Rohani M, Lang AE, Azad Z, Habibi SAH, Alavi A, et al. Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.13933

BibTeX
@article{Amini2024,
  author = {Amini, Elahe and Rohani, Mohammad and Lang, Anthony E and Azad, Zahra and Habibi, Seyed Amir Hassan and Alavi, Afagh and Shahidi, Gholamali and Emamikhah, Maziar and Chitsaz, Ahmad},
  title = {Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.13933}
}
Kostenlos starten →